Total Payments
$2,091
2024 Payments
$894.74
Companies
14
Transactions
38
Medicare Patients
2,425
Medicare Billing
$2.9M
Payment Breakdown by Category
Food & Beverage$2,057 (98.4%)
Consulting$34.14 (1.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,057 | 37 | 98.4% |
| Consulting Fee | $34.14 | 1 | 1.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $509.86 | 3 | $0 (2024) |
| Amgen Inc. | $441.55 | 6 | $0 (2024) |
| Eisai Inc. | $226.18 | 5 | $0 (2024) |
| GlaxoSmithKline, LLC. | $171.69 | 4 | $0 (2022) |
| ARGENX US, INC. | $121.83 | 1 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $119.53 | 2 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $116.66 | 5 | $0 (2024) |
| Lundbeck LLC | $115.62 | 2 | $0 (2023) |
| Lilly USA, LLC | $80.37 | 3 | $0 (2024) |
| GENZYME CORPORATION | $67.29 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $894.74 | 14 | Alexion Pharmaceuticals, Inc. ($392.63) |
| 2023 | $863.26 | 16 | Amgen Inc. ($262.18) |
| 2022 | $320.01 | 7 | GlaxoSmithKline, LLC. ($158.43) |
| 2021 | $13.26 | 1 | GlaxoSmithKline, LLC. ($13.26) |
All Payment Transactions
38 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/14/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $23.58 | General |
| Category: Neurology | ||||||
| 11/12/2024 | ADMA BioManufacturing LLC | — | Consulting Fee | Cash or cash equivalent | $34.14 | General |
| 11/12/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $15.50 | General |
| Category: Bone Health | ||||||
| 09/24/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $27.89 | General |
| Category: Immunology | ||||||
| 08/09/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $27.59 | General |
| Category: Immunology | ||||||
| 07/24/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $122.10 | General |
| Category: Neurology | ||||||
| 07/22/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $21.74 | General |
| Category: Immunology | ||||||
| 04/16/2024 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Food and Beverage | In-kind items and services | $19.08 | General |
| Category: IMMUNOLOGY | ||||||
| 04/11/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $289.79 | General |
| Category: Rare Disease | ||||||
| 04/11/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $102.84 | General |
| Category: Rare Disease | ||||||
| 03/21/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $26.90 | General |
| Category: Immunology | ||||||
| 02/28/2024 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $140.87 | General |
| Category: Bone Health | ||||||
| 02/14/2024 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Food and Beverage | In-kind items and services | $30.26 | General |
| Category: IMMUNOLOGY | ||||||
| 02/06/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $12.46 | General |
| Category: Neurology | ||||||
| 12/08/2023 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $25.88 | General |
| 10/10/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $22.08 | General |
| 10/02/2023 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $44.08 | General |
| Category: Neurology | ||||||
| 09/28/2023 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $117.23 | General |
| Category: Rare Disease | ||||||
| 09/28/2023 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $23.96 | General |
| Category: Neurology | ||||||
| 09/21/2023 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $121.83 | General |
| Category: Immunology | ||||||
| 09/07/2023 | Amgen Inc. | Prolia (Biological) | Food and Beverage | In-kind items and services | $118.76 | General |
| Category: Bone Health | ||||||
| 08/17/2023 | GENZYME CORPORATION | NEXVIAZYME (Biological) | Food and Beverage | In-kind items and services | $33.21 | General |
| Category: Genetic Disease | ||||||
| 06/28/2023 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Food and Beverage | In-kind items and services | $19.20 | General |
| Category: IMMUNOLOGY | ||||||
| 06/14/2023 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $18.42 | General |
| Category: Bone Health | ||||||
| 04/25/2023 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $85.62 | General |
| Category: NEUROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 758 | 54,163 | $5.5M | $861,860 |
| 2022 | 16 | 556 | 42,765 | $4.3M | $708,399 |
| 2021 | 14 | 495 | 33,375 | $2.4M | $394,490 |
| 2020 | 18 | 616 | 42,253 | $4.8M | $983,099 |
Total Patients
2,425
Total Services
172,556
Medicare Billing
$2.9M
Procedure Codes
69
All Medicare Procedures & Services
69 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3245 | Injection, tildrakizumab, 1 mg | Office | 2023 | 13 | 1,900 | $951,786 | $207,336 | 21.8% |
| J2357 | Injection, omalizumab, 5 mg | Office | 2023 | 15 | 6,285 | $851,115 | $190,104 | 22.3% |
| J0517 | Injection, benralizumab, 1 mg | Office | 2023 | 11 | 1,170 | $608,226 | $134,504 | 22.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 75 | 5,520 | $489,238 | $101,542 | 20.8% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 11 | 6,865 | $898,834 | $71,983 | 8.0% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 15 | 2,830 | $1.1M | $71,762 | 6.3% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 19 | 21,000 | $111,510 | $18,318 | 16.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 57 | 184 | $92,000 | $15,781 | 17.2% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 112 | 321 | $96,300 | $15,622 | 16.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 86 | 254 | $63,500 | $10,750 | 16.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 98 | 110 | $23,100 | $8,175 | 35.4% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 17 | 271 | $33,875 | $3,689 | 10.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 50 | 50 | $12,250 | $3,511 | 28.7% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 31 | 112 | $14,000 | $2,073 | 14.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 23 | 23 | $7,935 | $1,927 | 24.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 48 | 172 | $8,600 | $1,616 | 18.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 18 | 61 | $15,250 | $1,161 | 7.6% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2023 | 16 | 6,900 | $16,560 | $1,104 | 6.7% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 15 | 75 | $18,900 | $482.69 | 2.6% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 14 | 27 | $3,375 | $278.91 | 8.3% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2023 | 14 | 33 | $2,302 | $138.01 | 6.0% |
| J3245 | Injection, tildrakizumab, 1 mg | Office | 2022 | 17 | 3,000 | $1.5M | $324,735 | 21.6% |
| J0517 | Injection, benralizumab, 1 mg | Office | 2022 | 11 | 840 | $465,114 | $103,348 | 22.2% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2022 | 20 | 3,580 | $1.5M | $102,313 | 6.8% |
| J2357 | Injection, omalizumab, 5 mg | Office | 2022 | 12 | 2,700 | $365,634 | $80,146 | 21.9% |
About Deborah Herterich, FNP
Deborah Herterich, FNP is a Family healthcare provider based in Bedford, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2005. The National Provider Identifier (NPI) number assigned to this provider is 1437158383.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Deborah Herterich, FNP has received a total of $2,091 in payments from pharmaceutical and medical device companies, with $894.74 received in 2024. These payments were reported across 38 transactions from 14 companies. The most common payment nature is "Food and Beverage" ($2,057).
As a Medicare-enrolled provider, Herterich has provided services to 2,425 Medicare beneficiaries, totaling 172,556 services with total Medicare billing of $2.9M. Data is available for 4 years (2020–2023), covering 69 distinct procedure/service records.
Ad
Practice Information
- Specialty Family
- Location Bedford, TX
- Active Since 07/21/2005
- Last Updated 12/19/2016
- Taxonomy Code 363LF0000X
- Entity Type Individual
- NPI Number 1437158383
Products in Payments
- ULTOMIRIS (Biological) $509.86
- EVENITY (Biological) $299.79
- Leqembi (Drug) $226.18
- NUCALA (Biological) $147.39
- VYVGART (Drug) $121.83
- TEZSPIRE (Biological) $121.72
- Prolia (Biological) $118.76
- VYEPTI (Biological) $115.62
- HYQVIA (Biological) $68.54
- OMVOH (Drug) $54.49
- LUMIZYME (Biological) $34.08
- NEXVIAZYME (Biological) $33.21
- TREMFYA (Drug) $27.89
- ENTYVIO (Biological) $26.04
- BENLYSTA (Biological) $24.30
- STELARA (Biological) $21.74
- FASENRA (Biological) $20.81
- DALVANCE (Drug) $19.05
- RENFLEXIS (Drug) $17.87
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Doctors in Bedford
Muna Bhattarai, Fnp, FNP
Family — Payments: $10,825
Family $10,825
Michelle White, Fnp-C, FNP-C
Family — Payments: $5,657
Family $5,657
Kathryn Boyko, Aprn-Cnp, APRN-CNP
Family — Payments: $4,051
Family $4,051
Nicholas Montgomery
Family — Payments: $2,851
Family $2,851
Erick Arellano, Aprn, Fnp-C, APRN, FNP-C
Family — Payments: $2,563
Family $2,563
Kayla Wilt, Crnp, CRNP
Family — Payments: $2,248
Family $2,248